NCT Number: NCT00002040
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Both newly diagnosed and relapsed patients are eligible. The effectiveness of maintenance fluconazole therapy in sustaining a clinical cure in AIDS patients will also be evaluated.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Concurrent Medication:
Allowed:
- Antivirals such as zidovudine. Prophylaxis for Pneumocystis carinii pneumonia. Aerosolized pentamidine.
Concurrent Treatment:
Allowed:
- Radiation therapy for mucocutaneous Kaposi's sarcoma.
Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.
- Patient's treatment status must be one of the following:
- No prior systemic antifungal therapy for cryptococcosis.
- Relapse after prior therapy. The success of prior therapy must have been documented by negative CSF culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into the study.
Prior Medication:
Allowed:
- Antivirals such as zidovudine (AZT). Prophylaxis for Pneumocystis carinii pneumonia. Aerosolized pentamidine.
Exclusion criteria
Co-existing Condition:
Patients with the following are excluded:
- Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
- A history of allergy to or intolerance of imidazoles or azoles.
- Moderate or severe liver disease defined by specified lab values.
- Life expectancy of < 2 weeks.
Concurrent Medication:
Excluded:
- Coumarin-type anticoagulants.
- Oral hypoglycemics.
- Barbiturates.
- Phenytoin.
- Immunostimulants.
- Investigational drugs or approved (licensed) drugs for investigational indications except aerosolized pentamidine.
Concurrent Treatment:
Excluded:
- Lymphocyte replacement.
Patients with the following are excluded:
- Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
- A history of allergy to or intolerance of imidazoles or azoles.
- Moderate or severe liver disease defined by specified lab values.
- Life expectancy of < 2 weeks.
Prior Medication:
Excluded:
- Coumarin-type anticoagulants.
- Oral hypoglycemics.
- Barbiturates.
- Phenytoin.
- Immunostimulants.
- Investigational drugs or approved (licensed) drugs for investigational indications except aerosolized pentamidine.
Prior Treatment:
Excluded:
- Lymphocyte replacement.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
NCT00000639
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsDexamethasone in Cryptococcal Meningitis
NCT00000776
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial DetailsComparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
NCT00001017
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsMulti-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
NCT00000708
AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
Miami, Florida, United States
View Trial Details